Powered by: Motilal Oswal
2026-08-11 12:45:00 pm | Source: Accord Fintech
Gland Pharma zooms on reporting 47% jump in Q1 consolidated net profit
Gland Pharma zooms on reporting 47% jump in Q1 consolidated net profit

Gland Pharma is currently trading at Rs. 2876.85, up by 213.35 points or 8.01% from its previous closing of Rs. 2663.50 on the BSE.

The scrip opened at Rs. 2837.55 and has touched a high and low of Rs. 2989.25 and Rs. 2810.10 respectively. So far 379373 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2,989.25 on 11-Aug-2026 and a 52 week low of Rs. 1575.00 on 16-Mar-2026.

Last one week high and low of the scrip stood at Rs. 2,989.25 and Rs. 2531.60 respectively. The current market cap of the company is Rs. 47421.32 crore.

The promoters holding in the company stood at 51.77%, while Institutions and Non-Institutions held 39.18% and 9.05% respectively.

Gland Pharma has reported 35.33% jump in its net profit at Rs 364.39 crore for the first quarter ended June 30, 2026 (Q1FY27) as compared to Rs 269.26 crore for the same quarter in the previous year. The total income of the company has increased by 23.03% at Rs 1,345.46 crore for Q1FY27 as compared to Rs 1,093.58 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 47.09% jump in its net profit at Rs 316.96 crore for Q1FY27 as compared to Rs 215.48 crore for the same quarter in the previous year. The total income of the company has increased by 19.09% at Rs 1,861.50 crore for Q1FY27 as compared to Rs 1,563.15 crore for the corresponding quarter previous year.

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here